Idiopathic Infertility
Conditions
Keywords
Idiopathic, Infertility, coenzyme q10, Pakistan
Brief summary
To study the effect of coenzyme Q10 on semen parameters in men with idiopathic infertility
Detailed description
Decreased serum CoQ10 concentrations as well as a decrease in the CoQ10H2 to-ubiquinone ratio have been demonstrated in diseases associated with OS. A strong correlation among sperm count, motility and ubiquinol-10 levels in seminal fluid has also been reported. The aim of the present study is to investigate whether the effects of the exogenous administration of ubiquinol in the improvement of semen parameters in Pakistani men population. Patients who full filled the inclusion criteria and gave informed written consent will be included in the trial. Patient will start to take medication and will take it for 26 weeks. All men undergo a thorough physical examination, a detail history, serum biochemical and hematological laboratory tests and measurement of serum sex and thyroid hormone levels. A questionnaire will be used to collect information on demographic characteristics. Two semen samples 1 and 2 month apart will be obtained after 3 to 5 days of sexual abstinence and process within 1 hour of ejaculation. The mean of the two will be used for statistical analysis. Semen analyses will be performed using WHO recommended methods. 3 ml of blood will be withdrawn from the patient for the serum hormones analysis and total amount of semen will required for analysis of semen parameters. Sponsor will bear the test cost of patient during the study treatment period.
Interventions
DRUGCoenzyme Q10
200 mg of CoQ10 or placebo daily by mouth from day 1 till 26 weeks. CoQ10 treatment is safe, even at the highest doses cited in the literature. Most clinical trials have not reported significant adverse effects that necessitated stopping therapy. However, gastrointestinal effects such as abdominal discomfort, nausea, vomiting, diarrhea, and anorexia have occurred. Allergic rash and headache have also been reported
Sponsors
PharmEvo Pvt Ltd
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
20 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
* To sign the Informed Consent form * Patients will be recruited in the study if they will fulfilled the criteria of history of primary infertility of more than 2 years, abnormal sperm count and motility * age between 20 and 50 years * No known medical or surgical condition which can result in infertility
Exclusion criteria
* Voluntary withdrawal * Poor compliance of visit/treatment * A history of cancer chemotherapy or radiotherapy * A history of genital disease such as cryptorchidism and varicocele; a history of genital surgery * Body mass index 30 kg/m or greater; any endocrinopathy * Ychromosome microdeletions or karyotype abnormalities * leukocytospermia * Drug or substance abuse; tobacco use; * Use of anticonvulsants, androgens or antiandrogens * Significant liver (serum bilirubin greater than 2.0 mg/dl) * Renal function (serum creatinine greater than 2.0 mg/dl) impairment * Patients with severe oligozoospermia (less than 5 X 106/ml), azoospermia and testicular volume less than 12 ml will also excluded from study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Measure the change in semen parameters after 26 Weeks of coenzyme q10. | 26 weeks | To measure the change in semen parameters after 26 Weeks of coenzyme q10. Designated as safety issue: No |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Adverse Event | 26 weeks | Proportion of participants experiencing an adverse event (AE) leading to permanent discontinuation of study medication \[Designated as safety issue: Yes\] |
Countries
Pakistan
Outcome results
None listed